Filing Flows › Pyxis Oncology (PYXS) › Q4 2025
Pyxis Oncology (PYXS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 23, 2026
Pyxis Oncology (PYXS) reported revenue of $11.0M for the fourth quarter 2025 (Q4 2025). Operating margin was -165.7%, net loss $18.1M (164.0% of revenue).
Pyxis Oncology, Q4 2025: revenue $11.0M, operating margin -165.7%, net loss $18.1M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.0M | — | — |
| Operating profit | −$18.3M | — | — |
| Net earnings | −$18.1M | — | — |
| Operating cash flow | −$10.4M | — | — |
What changed
Revenue was $11.0M in Q4 2025.
Operating costs exceeded revenue by $18.3M, an operating margin of -165.7%. The quarter ended with a net loss of $18.1M.
Operating cash flow was −$10.4M. Non-cash charges added back $2.9M of depreciation and amortization and $2.1M of share-based compensation. Working capital and other items added $2.7M.
Questions
What was Pyxis Oncology's revenue in the fourth quarter 2025?
Pyxis Oncology (PYXS) reported revenue of $11.0M for the fourth quarter 2025 (Q4 2025).
Was Pyxis Oncology profitable in the fourth quarter 2025?
Operating loss was $18.3M (-165.7% of revenue) and net loss $18.1M.
Source: Pyxis Oncology 10-K on SEC EDGAR.